MRS 2211 MF: C14H10N4O8Na2PCl
MW: 474.66
A competitive P2Y13 receptor antagonist.

MRS 2211

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 111ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Application: MRS 2211 is a competitive P2Y13 receptor antagonist
Purity: ≥97%
Molecular Weight: 474.66
Molecular Formula: C14H10N4O8Na2PCl
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
loading

MRS 2211 is a selective and competitive P2Y13 receptor antagonist. Studies indicate that MRS 2211 displays greater selectivity towards P2Y1 over P2Y12 receptors. It is known that MRS 2211 inhibits ADP-induced inositol trisphosphate (IP3) formation. Research suggests that MRS 2211 inhibits phospholipase C (PLC) response to 2-methylthio-ADP in 1321N1 astrocytoma cells. P2Y receptors are important membrane proteins which function in cell-cell signaling and once activated inhibit adenylate cyclase activity. Furthermore, MRS 2211 is an essential tool in studying cell-cell signaling through the P2Y13 receptor and its effects on adenylate cyclase.


References

1. Kim, Y.C., et al. 2005. Biochem. Pharmacol. 70 266-274. PMID: 15913566
2. von Kügelgen, I. 2006. Pharmacol. Ther. 110: 415-432. PMID: 16257449

Physical State :
Solid
Solubility :
Soluble in water (70 mM).
Storage :
Desiccate at -20° C
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
SMILES :
O=Cc1c(COP(=O)(O[Na])O[Na])c(/N=N/c2cc(ccc2Cl)[N+](=O)[O-])nc(C)c1O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

MRS 2211  Product Citations

See how others have used MRS 2211. Click on the entry to view the PubMed entry .

Citations 1 to 2 of 2 total

PMID: # 33986729  Cao, X.|Ye, X.|Zhang, S.|Wang, L.|Xu, Y.|Peng, S.|Zhou, Y.|Peng, Y.|Li, J.|Zhang, X.|Han, X.|Huang, WY.|Jia, W.|Ye, J.| et al. 2021. Front Endocrinol (Lausanne). 12: 663530.

PMID: # 32641297  Aroua, N.|Boet, E.|Ghisi, M.|Nicolau-Travers, ML.|Saland, E.|Gwilliam, R.|de Toni, F.|Hosseini, M.|Mouchel, PL.|Farge, T.|Bosc, C.|Stuani, L.|Sabatier, M.|Mazed, F.|Larrue, C.|Jarrou, L.|Gandarillas, S.|Bardotti, M.|Picard, M.|Syrykh, C.|Laurent, C.|Gotanègre, M.|Bonnefoy, N.|Bellvert, F.|Portais, JC.|Nicot, N.|Azuaje, F.|Kaoma, T.|Joffre, C.|Tamburini, J.|Récher, C.|Vergez, F.|Sarry, JE.| et al. 2020. Cancer Discov. 10: 1544-1565.

Citations 1 to 2 of 2 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 105ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 7ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;